Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tubeimoside I (TBMS1) is a triterpenoid saponin isolated from the tubers of *Bolbostemma paniculatum* (Maxim.) Franquet, a plant used in traditional Chinese medicine known as Tu Bei Mu. It has demonstrated potent antitumor, anti-inflammatory, and anti-proliferative activities in various preclinical models. The compound primarily induces apoptosis in cancer cells, such as the human cervical carcinoma HeLa cell line, by triggering the mitochondrial pathway. This mechanism involves the opening of the mitochondrial permeability transition (PT) pore, which leads to a decrease in mitochondrial transmembrane potential and the subsequent release of cytochrome c into the cytosol. This release activates the caspase cascade, ultimately resulting in programmed cell death. Research also suggests that TBMS1 may have potential in treating other conditions due to its anti-inflammatory and antiviral properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tubeimoside I.